Clinical trial NCT02022501: A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
Official title: A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Age-Related Macular Degeneration
Keywords: Macular Degeneration
Lead sponsor: Santen Inc.
Sponsor class: INDUSTRY
First posted: 2013-12-27
Enrollment: 10
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.

Detailed description: This is an open-label, dose-escalating, sequential-cohort study of DE-120 injectable solution administered in 9, and up to 12, subjects with late stage exudative age-related macular degeneration.

Three cohorts of 3 subjects will receive a single intravitreal injection in the study eye. Subjects in Cohort 1 will receive a single intravitreal injection of Low Dose DE-120 injectable solution in the study eye and will be evaluated through Visit 5 (Month 1). If the Low Dose is considered to be safe, the next higher dose will be administered to Cohort 2.

The same enrollment and safety review procedures will be followed for Cohort 2 (Medium Dose DE-120) and Cohort 3 (High Dose DE-120).

Eligibility criteria: Main Inclusion Criteria:

* Understand and provide signed written informed consent
* Diagnosis of chronic subretinal or intraretinal fluid secondary to exudative age-related macular degeneration in the study eye
* At least one lesion in the study eye that meets minimal pathology criteria
* Visual acuity of ≤ 55 ETDRS letter (20/80 Snellen equivalent) or worse in the study eye, excluding No Light Perception
* Reasonably clear media and some fixation in the study eye

Main Exclusion Criteria:

Ocular

* Visual acuity of No Light Perception
* Aphakic or has an anterior chamber intraocular lens in the study eye.
* Use or anticipated use of any intravitreal, periocular or photodynamic therapy in the study eye for the treatment of AMD within a specified timeframe prior to Visit 1
* Uncontrolled glaucoma, chronic hypotony or vitrectomy in the study eye
* Evidence of any other ocular disease other than late stage exudative age related macular degeneration in the study eye that may confound the outcome of the study .
* Proscribed ocular surgery in the study eye either prior to or during the course of the trial
* Presence or history of certain ocular or periocular pathology or conditions that could limit ability to perform required study assessments in either eye and/or confound study results

Non-Ocular

* Systemic treatment with anti-VEGF agents (e.g., bevacizumab) is prohibited at any time during the study
* Allergy or hypersensitivity to study drug product, fluorescein dye, or other study related procedures/medications.
* Current or history of certain systemic conditions, abnormalities or therapies that would render a subject a poor candidate for a clinical trial
* Participation in other investigational drug or device clinical trials within 30 days prior to Screening or planning to participate in other investigational drug or device clinical trials for the duration of the study
* Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions and men who do not agree to practice an acceptable method of contraception throughout the course of the study
* Unable to comply with study procedures or follow-up visits

Primary outcomes:
measure: Number of subjects with adverse events
timeFrame: Each visit from Day 1 to Study Exit (Month 24)
measure: Change from Baseline in central subfield thickness (CST)
timeFrame: Each visit from Day 1 through Study Exit (Month 24)
measure: Change from Baseline in macular volume
timeFrame: Each visit from Day 1 through Study Exit (Month 24)
measure: Drug concentration in plasma over time after a single injection of DE-120
timeFrame: Most visits from Day 1 through Study Exit (Month 24)
Secondary outcomes:
measure: Change from Baseline in ocular signs and symptoms
timeFrame: Each visit from Day 1 through Study Exit (Month 24)
Other outcomes:
Locations:
city: Bakersfield
country: United States
state: California
city: Beverly Hills
country: United States
state: California
city: Dallas
country: United States
state: Texas
Study officials:
References: